Balance Sheet Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 16:17:13 21/01/2026 GMT			5-day change	1st Jan Change
68.48 ^USD	+4.90%		+2.99%	+2.24%

01-13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI
01-12	Arrowhead Pharmaceuticals issues $700 million of 0.00% convertible notes due 2032 - SEC filing	RE

b8c1bafa082cf48092ecea.VRBD48XMt4pATOasSVXMczeKfQ5UBQt8pUZVNfI6CGY.FlY0kIe4x6cMJo7dfmaVHQ_IGmY9f10z_H4McaNUTgglJTOIg4_G3Hgipw

Published financial data: ARROWHEAD PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: September	2021	2022	2023	2024	2025
Revenues	138M	243M	241M	3.55M	829M
Total Revenues	138M	243M	241M	3.55M	829M
Gross Profit	138M	243M	241M	3.55M	829M
Selling General & Admin Expenses, Total	88.68M	137M	109M	113M	139M
Stock-Based Compensation (IS)	-	-	-	-	-
R&D Expenses	199M	284M	337M	491M	593M
Depreciation & Amortization - (IS)	-	-	-	-	-
Other Operating Expenses, Total	287M	422M	446M	605M	731M
Operating Income	-149M	-179M	-205M	-601M	98.35M
Interest Expense, Total	-	-	-18.33M	-32.35M	-89.36M
Interest And Investment Income	6.12M	5.03M	15.3M	22.72M	37.29M
Net Interest Expenses	6.12M	5.03M	-3.03M	-9.63M	-52.07M
Other Non Operating Income (Expenses)	2.07M	5.2M	1.54M	-1.75M	5.26M
EBT, Excl. Unusual Items	-141M	-168M	-206M	-612M	51.53M
Gain (Loss) On Sale Of Investments	-	-4.43M	-	-	-
Asset Writedown	-	-	-	-	-
In Process R&D Expenses	-	-	-	-	-
Insurance Settlements	-	-	-	-	-
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	-141M	-173M	-206M	-612M	51.53M
Income Tax Expense	2K	3.78M	2.78M	-2.77M	21.42M
Earnings From Continuing Operations	-141M	-176M	-209M	-610M	30.11M
Net Income to Company	-141M	-176M	-209M	-610M	30.11M
Minority Interest	-	431K	4M	10.2M	-31.74M
Net Income - (IS)	-141M	-176M	-205M	-599M	-1.63M
Net Income to Common Incl Extra Items	-141M	-176M	-205M	-599M	-1.63M
Net Income to Common Excl. Extra Items	-141M	-176M	-205M	-599M	-1.63M
Per Share Items
Net EPS - Basic	-1.36	-1.67	-1.92	-5	-0.01
Basic EPS - Continuing Operations	-1.36	-1.67	-1.92	-5	-0.01
Basic Weighted Average Shares Outstanding	104M	105M	107M	120M	134M
Net EPS - Diluted	-1.36	-1.67	-1.92	-5	-0.01
Diluted EPS - Continuing Operations	-1.36	-1.67	-1.92	-5	-0.01
Diluted Weighted Average Shares Outstanding	104M	105M	107M	120M	134M
Normalized Basic EPS	-0.85	-0.99	-1.17	-3.11	0
Normalized Diluted EPS	-0.85	-0.99	-1.17	-3.11	0
American Depositary Receipts Ratio (ADR)	0.12	0.12	0.12	0.12	0.12
Supplemental Items
EBITDA	-141M	-168M	-193M	-582M	122M
EBITA	-147M	-177M	-203M	-599M	100M
EBIT	-149M	-179M	-205M	-601M	98.35M
EBITDAR	-131M	-152M	-173M	-566M	139M
Effective Tax Rate - (Ratio)	-0	-2.19	-1.35	0.45	41.56
Current Domestic Taxes	2K	304K	2.78M	523K	21.38M
Current Foreign Taxes	-	3.48M	-	-3.29M	35K
Total Current Taxes	2K	3.78M	2.78M	-2.77M	21.42M
Normalized Net Income	-88.03M	-105M	-125M	-373M	463K
Interest on Long-Term Debt	-	-	-	9.32M	63.32M
Supplemental Operating Expense Items
General and Administrative Expenses	78.64M	122M	89.13M	96.76M	122M
Research And Development Expense From Footnotes	206M	297M	353M	506M	607M
Net Rental Expense, Total	10.04M	15.86M	19.68M	16.69M	16.51M
Imputed Operating Lease Interest Expense	-	-	12.41M	6.99M	14.79M
Imputed Operating Lease Depreciation	-	-	7.27M	9.7M	1.72M
Stock-Based Comp., R&D Exp. (Total)	25.74M	32.37M	34.33M	33.59M	32.58M
Stock-Based Comp., G&A Exp. (Total)	50.93M	88.52M	43.8M	40.38M	30.78M
Stock-Based Comp., Other (Total)	-	1K	-	-	-
Total Stock-Based Compensation	76.67M	121M	78.13M	73.97M	63.37M

Fiscal Period: September	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	184M	108M	103M	99.18M	225M
Short Term Investments	183M	268M	293M	578M	693M
Total Cash And Short Term Investments	368M	376M	396M	677M	917M
Accounts Receivable, Total	10.26M	1.41M	-	-	6.82M
Total Receivables	10.26M	1.41M	-	-	6.82M
Prepaid Expenses	4.36M	7.29M	8.81M	9.54M	10.93M
Restricted Cash	-	-	7.9M	3.5M	1.9M
Other Current Assets, Total	2.19M	20.2M	7.08M	4.97M	13.52M
Total Current Assets	385M	405M	420M	695M	951M
Gross Property Plant And Equipment	88.88M	200M	378M	489M	507M
Accumulated Depreciation	-22.86M	-31.55M	-41.95M	-58.02M	-80.17M
Net Property Plant And Equipment	66.02M	169M	336M	431M	426M
Long-term Investments	246M	106M	-	-	-
Other Intangibles, Total	13.66M	11.96M	10.26M	8.56M	6.86M
Other Long-Term Assets, Total	272K	218K	210K	4.48M	1.39M
Total Assets	710M	692M	766M	1.14B	1.39B
Liabilities
Accounts Payable, Total	9.46M	2.87M	35.87M	11.39M	17.67M
Accrued Expenses, Total	20.67M	59.11M	57.73M	80.8M	96.24M
Short-term Borrowings	-	-	-	-	10.3M
Current Portion of Long-Term Debt	-	-	-	-	40M
Current Portion of Leases	2.25M	2.78M	10.56M	6.34M	7.29M
Current Income Taxes Payable	-	-	-	-	20.8M
Unearned Revenue Current, Total	114M	74.1M	866K	-	2.4M
Other Current Liabilities	-	-	435K	4.64M	788K
Total Current Liabilities	147M	139M	105M	103M	195M
Long-Term Debt	-	-	268M	735M	582M
Long-Term Leases	23.3M	78.8M	105M	111M	104M
Unearned Revenue Non Current	131M	55.95M	-	-	-
Other Non Current Liabilities	-	-	-	-	-
Total Liabilities	301M	274M	478M	949M	882M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	197K	198K	200K	217K	231K
Additional Paid In Capital	1.05B	1.22B	1.3B	1.81B	2.14B
Retained Earnings	-645M	-821M	-1.03B	-1.63B	-1.63B
Treasury Stock	-	-	-	-	-53.19M
Comprehensive Income and Other	-69K	-136K	-3.22M	4.75M	6.44M
Total Common Equity	409M	399M	271M	185M	466M
Minority Interest	-	19.82M	15.82M	5.62M	37.36M
Total Equity	409M	418M	287M	191M	503M
Total Liabilities And Equity	710M	692M	766M	1.14B	1.39B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	105M	106M	107M	124M	136M
ECS Total Common Shares Outstanding	104M	106M	107M	124M	136M
Book Value / Share	3.92	3.76	2.53	1.49	3.43
Tangible Book Value	395M	387M	261M	177M	459M
Tangible Book Value Per Share	3.79	3.65	2.43	1.42	3.38
Total Debt	25.54M	81.58M	383M	852M	744M
Net Debt	-342M	-295M	-12.23M	174M	-173M
Debt Equivalent Oper. Leases	80.3M	127M	157M	134M	132M
Minority Interest, Total (Incl. Fin. Div)	-	19.82M	15.82M	5.62M	37.36M
Account Code - Inventory Valuation	3	3	3	3	3
Land - (BS)	-	3M	3M	3M	3M
Buildings, Total	-	-	-	75.99M	251M
Machinery, Total	29.16M	40.46M	58.75M	71.93M	88M
Full Time Employees	329	397	525	609	711

Fiscal Period: September	2021	2022	2023	2024	2025
Net Income	-141M	-176M	-205M	-599M	-1.63M
Depreciation & Amortization - CF	6.57M	8.72M	10.79M	16.9M	22.23M
Amortization of Goodwill and Intangible Assets - (CF)	1.7M	1.7M	1.7M	1.7M	1.7M
Depreciation & Amortization, Total	8.27M	10.42M	12.49M	18.6M	23.93M
(Gain) Loss on Sale of Investments - (CF)	-	4.43M	-	80K	-
Asset Writedown & Restructuring Costs	-	-	-	-	-
Stock-Based Compensation (CF)	76.67M	121M	78.13M	73.97M	63.37M
Other Operating Activities, Total	266K	2.48M	12.31M	18.91M	112M
Change In Accounts Receivable	-9.41M	8.84M	1.41M	-	-56.97M
Change In Accounts Payable	2.63M	-6.59M	33M	-5.54M	6.29M
Change in Unearned Revenues	223M	-113M	-129M	-866K	2.4M
Change in Other Net Operating Assets	10.39M	11.95M	43.23M	31.49M	30.05M
Cash from Operations	171M	-136M	-154M	-463M	180M
Capital Expenditure	-23.57M	-52.78M	-177M	-141M	-22.67M
Investment in Marketable and Equity Securities, Total	-118M	47.36M	80.58M	-279M	-107M
Other Investing Activities, Total	-	-	-	-	-
Cash from Investing	-142M	-5.42M	-96.16M	-420M	-129M
Short Term Debt Issued, Total	-	-	-	-	10.26M
Long-Term Debt Issued, Total	-	-	-	392M	-
Total Debt Issued	-	-	-	392M	10.26M
Long-Term Debt Repaid, Total	-	-	-	-	-202M
Total Debt Repaid	-	-	-	-	-202M
Issuance of Common Stock	11.3M	5.19M	3.05M	432M	245M
Repurchase of Common Stock	-	-	-	-	-
Other Financing Activities, Total	-	60M	250M	46.87M	20M
Cash from Financing	11.3M	65.19M	253M	871M	74.01M
Foreign Exchange Rate Adjustments	-	-67K	-122K	4.2M	-401K
Net Change in Cash	40.85M	-76.43M	2.89M	-8.21M	124M
Supplemental Items
Cash Interest Paid	-	-	-	-	19K
Cash Income Tax Paid (Refund)	2K	2K	-	3.74M	-814K
Levered Free Cash Flow	63M	-53.34M	-254M	-440M	96.15M
Unlevered Free Cash Flow	63M	-53.34M	-243M	-420M	152M
Change In Net Working Capital	-94.77M	20.31M	28.77M	-4.67M	-25.91M
Net Debt Issued / Repaid	-	-	-	392M	-191M

Fiscal Period: September	2021	2022	2023	2024	2025
Profitability
Return on Assets	-15.11	-15.91	-17.58	-39.43	4.87
Return on Total Capital	-20.31	-23.88	-21.89	-43.85	5.37
Return On Equity %	-32.36	-42.67	-59.33	-254.98	8.67
Return on Common Equity	-32.36	-43.62	-61.29	-262.48	-0.5
Margin Analysis
Gross Profit Margin %	100	100	100	100	100
SG&A Margin	64.12	56.48	45.2	3.19K	16.7
EBITDA Margin %	-101.79	-69.11	-79.97	-16.4K	14.74
EBITA Margin %	-106.54	-72.69	-84.45	-16.88K	12.06
EBIT Margin %	-107.77	-73.39	-85.16	-16.93K	11.86
Income From Continuing Operations Margin %	-101.85	-72.56	-86.93	-17.17K	3.63
Net Income Margin %	-101.85	-72.38	-85.27	-16.88K	-0.2
Net Avail. For Common Margin %	-101.85	-72.38	-85.27	-16.88K	-0.2
Normalized Net Income Margin	-63.66	-43.06	-51.95	-10.49K	0.06
Levered Free Cash Flow Margin	45.55	-21.93	-105.7	-12.39K	11.59
Unlevered Free Cash Flow Margin	45.55	-21.93	-100.95	-11.83K	18.33
Asset Turnover
Asset Turnover	0.22	0.35	0.33	0	0.66
Fixed Assets Turnover	2.45	2.07	0.96	0.01	1.93
Receivables Turnover (Average Receivables)	24.91	41.7	-	-	-
Short Term Liquidity
Current Ratio	2.62	2.92	3.98	6.74	4.86
Quick Ratio	2.58	2.72	3.75	6.57	4.73
Operating Cash Flow to Current Liabilities	1.17	-0.98	-1.46	-4.49	0.92
Days Sales Outstanding (Average Receivables)	14.65	8.75	-	-	-
Long Term Solvency
Total Debt/Equity	6.25	19.5	133.55	445.88	147.79
Total Debt / Total Capital	5.88	16.32	57.18	81.68	59.64
LT Debt/Equity	5.7	18.84	129.87	442.56	136.35
Long-Term Debt / Total Capital	5.36	15.76	55.61	81.07	55.03
Total Liabilities / Total Assets	42.43	39.54	62.49	83.24	63.66
EBIT / Interest Expense	-	-	-11.19	-18.58	1.1
EBITDA / Interest Expense	-	-	-9.43	-17.49	1.55
(EBITDA - Capex) / Interest Expense	-	-	-19.07	-21.86	1.3
Total Debt / EBITDA	-0.2	-0.54	-2.22	-1.51	5.36
Net Debt / EBITDA	2.62	1.94	0.07	-0.31	-1.25
Total Debt / (EBITDA - Capex)	-0.17	-0.4	-1.1	-1.2	6.41
Net Debt / (EBITDA - Capex)	2.22	1.44	0.03	-0.25	-1.49
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	57.16	75.89	-1.03	-98.52	23.26K
Gross Profit, 1 Yr. Growth %	57.16	75.89	-1.03	-98.52	23.26K
EBITDA, 1 Yr. Growth %	61.4	19.41	14.53	202.58	-120.99
EBITA, 1 Yr. Growth %	61.1	20	14.99	194.82	-116.69
EBIT, 1 Yr. Growth %	59.98	19.77	14.84	193.21	-116.36
Earnings From Cont. Operations, 1 Yr. Growth %	66.58	25.31	18.57	191.34	-104.94
Net Income, 1 Yr. Growth %	66.58	25	16.59	192.04	-99.73
Normalized Net Income, 1 Yr. Growth %	66.58	17.56	16.32	197.93	-100.12
Diluted EPS Before Extra, 1 Yr. Growth %	61.9	22.8	15.15	160.27	-99.76
Accounts Receivable, 1 Yr. Growth %	1.11K	-86.25	-	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	40.42	155.36	99.04	28.53	-1.13
Total Assets, 1 Yr. Growth %	35.91	-2.56	10.64	48.89	21.54
Tangible Book Value, 1 Yr. Growth %	-11.48	-2.18	-32.46	-32.25	159.6
Common Equity, 1 Yr. Growth %	-11.47	-2.52	-31.91	-31.66	151.32
Cash From Operations, 1 Yr. Growth %	-279.5	-179.46	13.05	200.77	-138.79
Capital Expenditures, 1 Yr. Growth %	97.18	123.94	234.88	-19.96	-83.98
Levered Free Cash Flow, 1 Yr. Growth %	-180.07	-184.67	319.66	75.06	-121.85
Unlevered Free Cash Flow, 1 Yr. Growth %	-180.07	-184.67	300.77	74.99	-136.2
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-9.49	66.26	31.94	-87.92	85.62
Gross Profit, 2 Yr. CAGR %	-9.49	66.26	31.94	-87.92	85.62
EBITDA, 2 Yr. CAGR %	46.45	38.82	16.94	86.16	-20.3
EBITA, 2 Yr. CAGR %	53.06	39.04	17.47	84.12	-29.85
EBIT, 2 Yr. CAGR %	56.06	38.43	17.28	83.5	-30.74
Earnings From Cont. Operations, 2 Yr. CAGR %	43.95	44.48	21.89	85.86	-62.07
Net Income, 2 Yr. CAGR %	43.95	44.3	20.72	84.53	-91.09
Normalized Net Income, 2 Yr. CAGR %	43.76	40.77	19.19	86.16	-93.91
Diluted EPS Before Extra, 2 Yr. CAGR %	40.39	41	18.91	73.11	-92.04
Accounts Receivable, 2 Yr. CAGR %	293.78	29.1	-	-	-
Net Property, Plant and Equip., 2 Yr. CAGR %	68.64	89.36	125.45	59.94	12.73
Total Assets, 2 Yr. CAGR %	42.47	15.08	3.83	28.35	34.52
Tangible Book Value, 2 Yr. CAGR %	31.79	-6.95	-18.72	-32.36	32.62
Common Equity, 2 Yr. CAGR %	29.28	-7.1	-18.53	-31.78	31.06
Cash From Operations, 2 Yr. CAGR %	-0.52	19.2	-5.22	84.39	8.02
Capital Expenditures, 2 Yr. CAGR %	40.13	110.14	173.85	63.72	-64.19
Levered Free Cash Flow, 2 Yr. CAGR %	-28.64	-17.66	100.98	169.42	-38.16
Unlevered Free Cash Flow, 2 Yr. CAGR %	-28.64	-17.66	96.41	163.15	-20.41
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	104.62	12.95	39.86	-70.5	50.52
Gross Profit, 3 Yr. CAGR %	104.62	12.95	39.86	-70.5	50.52
EBITDA, 3 Yr. CAGR %	40.06	36.82	30.2	60.54	-10.06
EBITA, 3 Yr. CAGR %	39.53	41.14	30.51	59.64	-17.29
EBIT, 3 Yr. CAGR %	38.63	42.89	30.07	59.18	-18.02
Earnings From Cont. Operations, 3 Yr. CAGR %	37.27	37.44	35.27	62.97	-44.54
Net Income, 3 Yr. CAGR %	37.27	37.33	34.4	62.06	-79
Normalized Net Income, 3 Yr. CAGR %	37.27	34.98	33.25	61.76	-83.73
Diluted EPS Before Extra, 3 Yr. CAGR %	27.83	34.26	31.79	54.39	-80.6
Accounts Receivable, 3 Yr. CAGR %	215.23	28.7	-	-	69.15
Net Property, Plant and Equip., 3 Yr. CAGR %	67.95	93.65	92.53	86.94	36.25
Total Assets, 3 Yr. CAGR %	85.3	25.53	13.58	17.08	26.04
Tangible Book Value, 3 Yr. CAGR %	72.46	19.32	-16.37	-23.5	5.91
Common Equity, 3 Yr. CAGR %	62.2	17.67	-16.24	-23.16	5.36
Cash From Operations, 3 Yr. CAGR %	53.63	-7.68	17.12	39.28	9.67
Capital Expenditures, 3 Yr. CAGR %	155	63.84	145.45	81.74	-24.55
Levered Free Cash Flow, 3 Yr. CAGR %	28.75	-24.45	47.89	91.17	16.61
Unlevered Free Cash Flow, 3 Yr. CAGR %	28.75	-24.45	45.64	88.2	35.84
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	287.47	50.59	71.68	-53.8	56.63
Gross Profit, 5 Yr. CAGR %	287.47	50.59	71.68	-53.8	56.63
EBITDA, 5 Yr. CAGR %	11.33	39.08	30.31	54.75	6.99
EBITA, 5 Yr. CAGR %	11.94	38.02	30.25	56.97	1.81
EBIT, 5 Yr. CAGR %	11.74	36.99	29.66	57.92	1.09
Earnings From Cont. Operations, 5 Yr. CAGR %	11.5	38.7	30.9	55.08	-18.66
Net Income, 5 Yr. CAGR %	11.5	38.63	30.4	54.56	-54.6
Normalized Net Income, 5 Yr. CAGR %	10.49	37.28	29.73	54.3	-61.23
Diluted EPS Before Extra, 5 Yr. CAGR %	0.3	28.86	24.19	48.63	-57.11
Accounts Receivable, 5 Yr. CAGR %	167.41	83.49	-	-	51.82
Net Property, Plant and Equip., 5 Yr. CAGR %	33.82	61.15	88.94	79.39	55.42
Total Assets, 5 Yr. CAGR %	40.83	46.08	46.98	26.65	21.53
Tangible Book Value, 5 Yr. CAGR %	40.02	44.69	27.65	-4.91	0.57
Common Equity, 5 Yr. CAGR %	33.73	37.39	23.15	-5.39	0.18
Cash From Operations, 5 Yr. CAGR %	21.59	41.57	26.65	21.75	13.39
Capital Expenditures, 5 Yr. CAGR %	43.59	46.14	162.38	63.79	13.65
Levered Free Cash Flow, 5 Yr. CAGR %	13.31	18.76	53.85	28.9	4.1
Unlevered Free Cash Flow, 5 Yr. CAGR %	13.31	18.76	52.44	27.69	14.08